Acer Therapeutics (ACER) Stock: Gaining Big On Positive Clinical Data

0

Acer Therapeutics Inc (NASDAQ: ACER) is having an overwhelmingly strong start to the trading session this morning, and for good reason. The company released positive results from a key clinical trial, leading to excitement among investors and sending the stock toward the top. As is almost always the case, our partners at Trade Ideas were the first to alert us to the gains. Currently (9:47), ACER is trading at $11:80 per share after a gain of $0.80 per share (7.27%) thus far today.





ACER Gains Big On Positive Clinical Data

As mentioned above, Acer Therapeutics is having an overwhelmingly strong start to the trading session this morning after releasing positive clinical results. The results came from the trial of EDSIVOTM (celiprolol). The drug was designed for the treatment of vascular Ehlers-Danios Syndrome (vEDS). The study met both primary and secondary endpoints. The company said that it would be using this clinical data to support the New Drug Application in the United States in the first half of 2018. In a statement, Pierre Boutouyrie M.D., Ph.D., Co-Director of the Clinical Pharmacology Controlled Clinical Pharmacology Service at the Georges-Pompidou European Hospital, Greater Paris University Hospitals (AP-HP) and Principal Investigator in the ACER study, had the following to offer:




We have studied celiprolol for nearly two decades in vEDS patients and this is the only drug to ever demonstrate a clinical benefit in this difficult to treat patient population in a randomized, controlled clinical study… Having established celiprolol as the standard of care in France for vEDS patients, we are excited to collaborate with Acer to help bring celiprolol to U.S. patients who are suffering from this devastating, life-threatening disease.”

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on ACER. In particular, we’re interested in following the company through the ongoing work to bring celiprolol to the market. We’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









LEAVE A REPLY

Please enter your comment!
Please enter your name here